

October 15-17, 2013 Hampton Inn Tropicana, Las Vegas, NV, USA

## PD-L1/PD-1 co-stimulation, a brake for T cell activation and a T cell differentiation signal

David Escors<sup>1</sup>, Therese Liechtenstein<sup>1</sup>, Ines Dufait<sup>1,2</sup>, Christopher Bricogne<sup>1</sup>, Alessio Lanna<sup>1</sup>, Joeri Pen<sup>2</sup> and Karine Breckpot<sup>2</sup> <sup>1</sup>Division of Infection and Immunity, Rayne Institute, University College London, UK <sup>2</sup>Laboratory of Molecular and Cellular Therapy, Department of Physiology-Immunology, Vrije Universiteit Brussel, Belgium

 $\mathbf{F}_{2}$  (co-stimulation) and signal 3 (cytokine priming). Blocking negative co-stimulation during antigen presentation to T cells is becoming a promising therapeutic strategy to enhance cancer immunotherapy. Here we will focus on interference with PD-1/PD-L1 negative co-stimulation during antigen presentation to T cells as a therapeutic approach. We will discuss the potential mechanisms and the therapeutic consequences by which interference/inhibition with this interaction results in anti-tumour immunity. Particularly, we will comment on whether blocking negative co-stimulation provides differentiation signals to T cells undergoing antigen presentation. A major dogma in immunology states that T cell differentiation signals are given by cytokines and chemokines (signal 3) rather than co-stimulation (signal 2). We will discuss whether this is the case when blocking PD-L1/PD-1 negative co-stimulation.

d.escors@ucl.ac.uk